human pancreatic cancer cells pl45  (iCell Bioscience Inc)

Journal: bioRxiv

Article Title: FOLFIRINOX Combined with GPX4 Inhibition Induces Ferroptosis and Defines Redox-Based Therapeutic Subgroups in Pancreatic Cancer

doi: 10.1101/2025.09.12.675778

Figure Lengend Snippet: (A) Immunohistochemistry images for GPX4 and ROS (8-OHdG) staining in four PDAC cell lines (PL45, BxPC-3, PANC-1, and Panc04.03). (B) Semi-quantitative analysis of staining expressed as percentage of positive cells, intensity (0–3), and H-Score. (C) Chemical structure of RSL3. (D) Cell viability curves in response to RSL3 treatment (μM) in four cell lines. (E) Calculated IC₅₀ values for RSL3. (F) Cell viability curves in response to FOLFIRINOX treatment in logarithmic scale. (G) Individual IC₅₀ values for each FOLFIRINOX component (5-FU, leucovorin, irinotecan, and oxaliplatin) in mg/mL. Data represents the mean of three biological replicates.

Article Snippet: Human pancreatic cancer cell lines PL45, PANC-1, BxPC-3, and Panc04.03 were obtained from ATCC and cultured in DMEM or RPMI-1640 medium supplemented with 10% FBS and 1% P/S under standard conditions (37 °C, in a humidified atmosphere containing 5% CO2).

Techniques: Immunohistochemistry, Staining

Journal: bioRxiv

Article Title: FOLFIRINOX Combined with GPX4 Inhibition Induces Ferroptosis and Defines Redox-Based Therapeutic Subgroups in Pancreatic Cancer

doi: 10.1101/2025.09.12.675778

Figure Lengend Snippet: This figure shows dose-response curves for four pancreatic cancer cell lines (PL45, Panc04.03, BxPC-3, and PANC-1) treated with FOLFIRINOX (A-D) or RSL3 (E-H). Cell viability (%) is shown in y-axis while drug concentration is shown in x-axis. For FOLFIRINOX, the X-axis is log-transformed concentration; for RSL3, it is linear in μM. Each panel includes the best-fit equation and R² value. White boxes: RSL3-sensitive PDAC-derived cell lines; black boxes: RSL3-resistant PDAC-derived cell lines.

Article Snippet: Human pancreatic cancer cell lines PL45, PANC-1, BxPC-3, and Panc04.03 were obtained from ATCC and cultured in DMEM or RPMI-1640 medium supplemented with 10% FBS and 1% P/S under standard conditions (37 °C, in a humidified atmosphere containing 5% CO2).

Techniques: Concentration Assay, Transformation Assay, Derivative Assay

Journal: bioRxiv

Article Title: FOLFIRINOX Combined with GPX4 Inhibition Induces Ferroptosis and Defines Redox-Based Therapeutic Subgroups in Pancreatic Cancer

doi: 10.1101/2025.09.12.675778

Figure Lengend Snippet: Quantification of ferroptosis in PL45 (control mean ± 95% CI = 1.00 [0.45–1.55], FOLFIRINOX mean ± 95% CI = 1.67 [1.34–1.99]; FOLFIRINOX + RSL3 mean ± 95% CI = 2.66 [2.22–3.11]) (A), Panc04.03 (control mean ± 95% CI = 1.00 [0.52–1.48], FOLFIRINOX mean ± 95% CI = 1.01 [0.53–1.50]; FOLFIRINOX + RSL3 mean ± 95% CI = 2.48 [2.20–2.77])(B), BxPC-3 (control mean ± 95% CI = 1.00 [0.87–1.12], FOLFIRINOX mean ± 95% CI = 1.54 [1.27–1.81]; FOLFIRINOX + RSL3 mean ± 95% CI = 1.48 [1.21–1.75]) (C), and PANC-1 (control mean ± 95% CI = 1.21 [0.80–1.63], FOLFIRINOX mean ± 95% CI = 1.74 [1.13–2.34]; FOLFIRINOX + RSL3 mean ± 95% CI = 1.72 [1.46–1.97]) (D). Bar graphs show fold change in the ferroptosis ratio. Quantification of apoptosis in PL45 (control mean ± 95% CI = 1.00 [0.59–1.41], FOLFIRINOX mean ± 95% CI = 1.56 [0.81–2.31], FOLFIRINOX + RSL3 mean ± 95% CI = 2.94 [2.69–3.20]) (E), Panc04.03 (control mean ± 95% CI = 1.00 [0.66–1.34], FOLFIRINOX mean ± 95% CI = 2.51 [1.71–3.31], FOLFIRINOX + RSL3 mean ± 95% CI = 5.76 [3.02–8.50]) (F), BxPC-3 (control mean ± 95% CI = 1.00 [0.68–1.32], FOLFIRINOX mean ± 95% CI = 1.17 [0.95–1.38], FOLFIRINOX + RSL3 mean ± 95% CI = 0.82 [0.60–1.04]) (G), and PANC-1 (control mean ± 95% CI = 1.00 [0.55–1.28], FOLFIRINOX mean ± 95% CI = 1.75 [0.67–2.63], FOLFIRINOX + RSL3 mean ± 95% CI = 1.72 [0.24–2.54]) (H). Dot plots show Annexin V (x-axis) and propidium iodide (y-axis). Bar graphs show fold change in the apoptosis ratio (both early and late apoptosis). Quantification of intracellular ROS levels in PL45 (control mean ± 95% CI = 1.000 [0.914–1.086]; NAC mean ± 95% CI = 0.8460 [0.573–1.119]; FOLFIRINOX mean ± 95% CI = 0.8468 [0.625–1.069]; FOLFIRINOX + RSL3 mean ± 95% CI = 31.367 [1.132–1.601]; FOLFIRINOX + RSL3 + NAC mean ± 95% CI = 0.4424 [0.292– 0.593]) (I); Panc04.03 (control mean ± 95% CI = 1.011[0.750–1.272]; NAC mean ± 95% CI = 0.96 [0.80–1.11]; FOLFIRINOX mean ± 95% CI = 0.96 [0.67–1.25]; FOLFIRINOX + RSL3 mean ± 95% CI = 2.694 [2.328–3.061]; FOLFIRINOX +RSL3 + NAC mean ± 95% CI = 0.7553 [0.327–1.183]) (J); BxPC-3 (control mean ± 95% CI = 1.000 [0.643–1.357]; FOLFIRINOX mean ± 95% CI = 1.172 [1.084–1.267]; FOLFIRINOX + RSL3 mean ± 95% CI = 1.237 [1.170–1.305]) (K); and PANC-1 (control mean ± 95% CI = 1.013 [0.948–1.078]; FOLFIRINOX mean ± 95% CI = 0.6980 [0.768–1.185]; FOLFIRINOX + RSL3 mean ± 95% CI = 0.8678 [1.045–2.251]) (L). Bar graphs show fold change of intracellular ROS levels. Western blot quantification of GPX4 expression levels (PL45 control (mean ± 95 % CI: 0.9206 [0.1519 – 1.689]); PL45 FOLFIRINOX (mean ± 95 % CI: 2.373 [0.8821 – 3.863]); PL45 FOLFIRINOX + RSL3 (mean ± 95 % CI: 1.071 [–0.1754 – 2.318]); PL45 FOLFIRINOX + RSL3 + NAC (mean ± 95 % CI: 1.598 [0.5043 – 2.692]); Panc04.03 control (mean ± 95 % CI: 0.7333 [0.2162 – 1.250]); Panc04.03 FOLFIRINOX (mean ± 95 % CI: 1.500 [–0.01104 – 3.011]); Panc04.03 FOLFIRINOX + RSL3 (mean ± 95 % CI: 0.7667 [–0.6015 – 2.135]); Panc04.03 FOLFIRINOX + RSL3 + NAC (mean ± 95 % CI: 1.200 [0.5428 – 1.857]); BxPC-3 control (mean ± 95 % CI: 1.160 [0.4648 – 1.855]); BxPC-3 FOLFIRINOX (mean ± 95 % CI: 1.163 [0.9971 – 1.323]); BxPC-3 FOLFIRINOX + RSL3 (mean ± 95 % CI: 0.2615 [0.01392 – 0.5090]), PANC1 control (mean ± 95 % CI: 0.7926 [0.5111 – 1.074]); PANC1 FOLFIRINOX (mean ± 95 % CI: 0.6218 [0.4785 – 0.7650]); PANC1 FOLFIRINOX + RSL3 (mean ± 95 % CI: 0.1323 [0.06885 – 0.1957])); and SOD2 expression levels (PL45 control (mean ± 95% CI: 0.9972 [0.290– 1.704]); PL45 FOLFIRINOX (mean ± 95% CI: 1.409 [0.7315–2.086]); PL45 FOLFIRINOX + RSL3 (mean ± 95% CI: 1.624 [0.9175–2.330]); PL45 FOLFIRINOX + RSL3 + NAC (mean ± 95% CI: 1.458 [0.9079–2.008]); (Panc04.03 control (mean ± 95% CI: 0.55 [0.3194–1.419]); Panc04.03 FOLFIRINOX (mean ± 95% CI: 1.0 [0.1043–1.896]); Panc04.03 FOLFIRINOX + RSL3 (mean ± 95% CI: 0.8 [0.0957–1.696]); Panc04.03 FOLFIRINOX + RSL3 + NAC (mean ± 95% CI: 0.9 [0.1548–1.645]); BxPC-3 control (mean ± 95% CI: 0.861 [0.5527–1.169]); BxPC-3 FOLFIRINOX (mean ± 95% CI: 1.436 [0.7947–2.078]); BxPC-3 FOLFIRINOX + RSL3 (mean ± 95% CI: 1.873 [0.6964–4.443]); PANC1 control (mean ± 95% CI: 0.6098 [0.3236–0.896]); PANC1 FOLFIRINOX (mean ± 95% CI: 1.004 [0.6345–1.374]); PANC1 FOLFIRINOX + RSL3 (mean ± 95% CI: 1.101 [0.6139–1.588]), including representative bands and histograms normalized to actin expression for PL45 (M), Panc04.03 (N), BxPC-3 (O), and PANC-1 (P). Abbreviations: Control (C), N-acetyl-cysteine (NAC), FOLFIRINOX (F), FOLFIRINOX + RSL3 (F+R), and FOLFIRINOX + RSL3 + N-acetyl-cysteine (F+R+NAC). White boxes: RSL3-sensitive PDAC-derived cell lines; black boxes: RSL3-resistant PDAC-derived cell lines. Statistical significance was considered at p < 0.05 (n.s. = not significant).

Article Snippet: Human pancreatic cancer cell lines PL45, PANC-1, BxPC-3, and Panc04.03 were obtained from ATCC and cultured in DMEM or RPMI-1640 medium supplemented with 10% FBS and 1% P/S under standard conditions (37 °C, in a humidified atmosphere containing 5% CO2).

Techniques: Control, Western Blot, Expressing, Derivative Assay

Journal: bioRxiv

Article Title: FOLFIRINOX Combined with GPX4 Inhibition Induces Ferroptosis and Defines Redox-Based Therapeutic Subgroups in Pancreatic Cancer

doi: 10.1101/2025.09.12.675778

Figure Lengend Snippet: (A) Tumor growth kinetics (left) and final tumor volume analysis (right) of PL45 xenografts treated with control (blue), FOLFIRINOX (orange), or FOLFIRINOX + RSL3 (green). Arrows indicate the final day of chemotherapy administration. (B) Representative photographs of mice bearing PL45 tumors (left) and excised tumors per treatment group (right). (C) Tumor growth kinetics (left) and final tumor volumes (right) of PANC-1 xenografts under identical treatment conditions. (D) Representative photographs of mice bearing PANC-1 tumors (left) and excised tumors (right). The ruler is marked in centimeters (cm). (E–F) Comparative efficacy of FOLFIRINOX monotherapy and FOLFIRINOX + RSL3 combination in PL45 and PANC-1 models, respectively. (G–H) Body weight monitoring over time for PL45 and PANC-1 xenografts, respectively. Red arrows denote FOLFIRINOX dosing days. (I) Immunohistochemical staining of xenografts for intracellular ROS, GPX4, and SOD2 expression. Scale bar represents 100 µm.

Article Snippet: Human pancreatic cancer cell lines PL45, PANC-1, BxPC-3, and Panc04.03 were obtained from ATCC and cultured in DMEM or RPMI-1640 medium supplemented with 10% FBS and 1% P/S under standard conditions (37 °C, in a humidified atmosphere containing 5% CO2).

Techniques: Control, Immunohistochemical staining, Staining, Expressing

Journal:

Article Title: Thymosin beta 10 is Aberrantly Expressed in Pancreatic Cancer and Induces JNK Activation

doi: 10.1080/07357900802254016

Figure Lengend Snippet: Immunohistochemistry staining of Tβ10 in human pancreatic adenocarcinoma tissues.

Article Snippet: Human pancreatic cancer cell lines (Panc-1, BxPC-3, ASPC-1, Capan-2, HPAF-II, Panc 03.27, and PL45) were obtained from the American Type Culture Collection (ATCC, Rockville, MD).

Techniques: Immunohistochemistry, Staining, Expressing

Journal:

Article Title: Thymosin beta 10 is Aberrantly Expressed in Pancreatic Cancer and Induces JNK Activation

doi: 10.1080/07357900802254016

Figure Lengend Snippet: Immunostaining of Tβ10 in pancreatic adenocarcinoma tissues. Normal pancreatic tissue composed of acinar cells and ductal epithelial cells with negative immunostaining of Tβ10. Representative pancreatic ductal adenocarcinoma showed positive immunostaining of Tβ10. Dark brown color represents positive staining of Tβ10. Arrow head, normal ductal epithelial cells; arrow, tumor epithelial cells.

Article Snippet: Human pancreatic cancer cell lines (Panc-1, BxPC-3, ASPC-1, Capan-2, HPAF-II, Panc 03.27, and PL45) were obtained from the American Type Culture Collection (ATCC, Rockville, MD).

Techniques: Immunostaining, Staining

Journal:

Article Title: Thymosin beta 10 is Aberrantly Expressed in Pancreatic Cancer and Induces JNK Activation

doi: 10.1080/07357900802254016

Figure Lengend Snippet: Expression of Tβ10 mRNA in human pancreatic cancer tissues and cell lines. The Tβ10 mRNA expression in ten pairs of human pancreatic cancer specimens and surrounding normal tissues (A), and in seven human pancreatic cancer cells, and control HPDE cells (B), were determined by realtime RT PCR. All data shown are the mean±SEM of three separate experiments. *p < 0.05 as compared to normal tissue or control HPDE cells.

Article Snippet: Human pancreatic cancer cell lines (Panc-1, BxPC-3, ASPC-1, Capan-2, HPAF-II, Panc 03.27, and PL45) were obtained from the American Type Culture Collection (ATCC, Rockville, MD).

Techniques: Expressing, Control, Reverse Transcription Polymerase Chain Reaction

Journal:

Article Title: Thymosin beta 10 is Aberrantly Expressed in Pancreatic Cancer and Induces JNK Activation

doi: 10.1080/07357900802254016

Figure Lengend Snippet: Effect of Tβ10 on cytokine secretion in pancreatic cancer cells. Supernatants from Tβ10-treated BxPC-3 cells were collected after 24 h. Cytokine levels were determined by Bio-plex cytokine assay. The values plotted are the percentage increase to the non-treated cells. Data are expressed as mean±SEM of duplicate values from two separate experiments. *p < 0.05 as compared to Tβ10-untreated controls.

Article Snippet: Human pancreatic cancer cell lines (Panc-1, BxPC-3, ASPC-1, Capan-2, HPAF-II, Panc 03.27, and PL45) were obtained from the American Type Culture Collection (ATCC, Rockville, MD).

Techniques: Cytokine Assay